OLANZAPINE Side Effects

7014395-6 | Weight Increased
on Sep 14, 2010 Male patient from AUSTRALIA , 28 years of age, was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: weight increased. Olanzapine dosage: .

7008619-9 | Off Label Use, Platelet Count Decreased
Patient was taking Olanzapine (View Usage). Patient had the following side effects: off label use, platelet count decreased on Sep 09, 2010 from JAPAN Additional patient health information: Female patient , 85 years of age, . Olanzapine dosage: 10 Mg, Daily (1/d). During the same period patient was treated with VALPROIC ACID (View Valproic Acid Review and Valproic Acid Label ).

7005946-6 | Fatigue, Psychotic Disorder, Somnolence, Suicidal Ideation, Suicide Attempt
Adverse event was reported on Sep 08, 2010 by a Male patient taking Olanzapine (View Usage) (Dosage: 210 Mg Every Four Weeks) was diagnosed with schizophrenia and. Location: GERMANY , weighting 176.4 lb, After Olanzapine was administered, patient had the following side effects: fatigue, psychotic disorder (What is psychotic disorder?), somnolence, suicidal ideation, suicide attempt. Patient was hospitalized.

7003301-6 | Hallucination, Auditory, Oculogyric Crisis
on Sep 07, 2010 Male patient from INDIA , 30 years of age, was diagnosed with schizophrenia, paranoid type and was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: hallucination, auditory, oculogyric crisis. Olanzapine dosage: 2.5 Mg, Daily (1/d). Patient was hospitalized.


7003290-4 | Hallucination, Auditory, Oculogyric Crisis, Suicidal Ideation
on Sep 07, 2010 Female patient from INDIA , 35 years of age, was diagnosed with schizophrenia, paranoid type and was treated with Olanzapine (View Usage). Patient had the following side effects: hallucination, auditory, oculogyric crisis, suicidal ideation. Olanzapine dosage: 20 Mg, Daily (1/d). Patient was hospitalized.

6974870-7 | Schizophrenia
Patient was taking Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: schizophrenia on Sep 01, 2010 from JAPAN Additional patient health information: Male patient , 57 years of age, weighting 121.3 lb, was diagnosed with schizophrenia, disorganised type and. Olanzapine dosage: 20 Mg, Daily (1/d). During the same period patient was treated with VALPROATE SODIUM (1200 Mg, Daily (1/d)) (View Valproate Sodium Review and Valproate Sodium Label ). Patient was hospitalized.

6974543-0 | Agranulocytosis, Leukopenia, Neutrophil Count Decreased
Adverse event was reported on Sep 09, 2010 by a Male patient taking Olanzapine (View Usage) (Dosage: 30 Mg At Bedtime Po) was diagnosed with schizophrenia, paranoid type and. Location: UNITED STATES , 30 years of age, weighting 192.5 lb, Patient experienced the following unwanted or unexpected effects: agranulocytosis, leukopenia, neutrophil count decreased.

6970064-X | Hallucination, Auditory, Homicide, Obesity
on Aug 26, 2010 Male patient from CANADA , 41 years of age, was diagnosed with schizophrenia and was treated with Olanzapine (View Usage). Patient had the following side effects: hallucination, auditory, homicide, obesity (What is obesity?). Olanzapine dosage: 20 Mg, Each Evening.

6968164-3 | Respiratory Arrest
on Aug 31, 2010 Female patient from JAPAN , 39 years of age, was diagnosed with schizophrenia, paranoid type and was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: respiratory arrest. Olanzapine dosage: 15 Mg, Daily (1/d).

6965109-7 | Mood Swings
Patient was taking Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: mood swings on Aug 24, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 112.0 lb, was diagnosed with bipolar i disorder, bipolar disorder (What is bipolar disorder?) and. Olanzapine dosage: 7.5 Mg, Daily (1/d). During the same period patient was treated with LITHIUM /00033701/ (300 Mg, 2/d) (View Lithium /00033701/ Review and Lithium /00033701/ Label ). Patient was hospitalized.

6961529-5 | Benign Intracranial Hypertension, Headache, Nausea, Papilloedema, Vision Blurred, Weight Increased
Adverse event was reported on Aug 23, 2010 by a Female patient taking Olanzapine (View Usage) (Dosage: 15 Mg/day) was diagnosed with bipolar disorder (What is bipolar disorder?) and. Location: TURKEY , 38 years of age, Patient had the following side effects: benign intracranial hypertension, headache (What is headache?), nausea (What is nausea?), papilloedema, vision blurred, weight increased. During the same period patient was treated with PAROXETINE (NGX) (40 Mg/day) (View Paroxetine (ngx) Review and Paroxetine (ngx) Label ), VALPROIC ACID (1000 Mg/day) (View Valproic Acid Review and Valproic Acid Label ).

6960103-4 | Dizziness, Hot Flush, Vision Blurred
on Aug 19, 2010 Male patient from UNITED STATES , weighting 213.2 lb, was diagnosed with schizoaffective disorder and was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: dizziness (What is dizziness?), hot flush, vision blurred. Olanzapine dosage: 300 Mg, Monthly (1/m). During the same period patient was treated with ZANTAC (150 Mg, 2/d) (View Zantac Review and Zantac Label ), LORATADINE (10 Mg, 2/d) (View Loratadine Review and Loratadine Label ), WELLBUTRIN SR (150 Mg, Daily (1/d)) (View Wellbutrin Sr Review and Wellbutrin Sr Label ), DEPAKOTE ER (1000 Mg, 2/d) (View Depakote Er Review and Depakote Er Label ), ABILIFY (10 Mg, Each Evening) (View Abilify Review and Abilify Label ).

6957818-0 | Clonic Convulsion, Inappropriate Antidiuretic Hormone Secretion, Respiratory Arrest
on Aug 19, 2010 Female patient from UNITED KINGDOM , 48 years of age, was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: clonic convulsion, inappropriate antidiuretic hormone secretion, respiratory arrest. Olanzapine dosage: 20 Mg, Daily (1/d). During the same period patient was treated with DIAZEPAM (5 Mg, Daily (1/d)) (View Diazepam Review and Diazepam Label ), SIMVASTATIN (40 Mg, Daily (1/d)) (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6942862-X | Aortic Arteriosclerosis, Arteriosclerosis Coronary Artery, Bladder Hypertrophy, Coronary Artery Stenosis, Hepatic Steatosis, Left Ventricular Hypertrophy, Off Label Use, Pancreatic Disorder
Patient was taking Olanzapine (View Usage). Patient had the following side effects: aortic arteriosclerosis, arteriosclerosis coronary artery, bladder hypertrophy, coronary artery stenosis, hepatic steatosis, left ventricular hypertrophy, off label use, pancreatic disorder on Aug 12, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 27 years of age, weighting 122.0 lb, was diagnosed with anxiety (What is anxiety?), depression (What is depression?) and. Olanzapine dosage: 5 Mg, 4/d. During the same period patient was treated with CITALOPRAM HYDROBROMIDE (40 Mg, Unk) (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), DF118 (30 Mg, 4/d) (View Df118 Review and Df118 Label ), GABAPENTIN (300 Mg, Unk) (View Gabapentin Review and Gabapentin Label ), CANNABIS (View Cannabis Review and Cannabis Label ).

6919012-9 | Sedation
Adverse event was reported on Jul 28, 2010 by a Female patient taking Olanzapine (View Usage) (Dosage: ) was diagnosed with bipolar disorder (What is bipolar disorder?) and. Location: UNITED KINGDOM , 22 years of age, After Olanzapine was administered, patient had the following side effects: sedation.

6918999-8 | No Therapeutic Response, Overdose, Psychiatric Decompensation
on Jul 28, 2010 Male patient from UNITED KINGDOM , 25 years of age, was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: no therapeutic response, overdose, psychiatric decompensation. Olanzapine dosage: .

6914874-3 | Cognitive Disorder, Expressive Language Disorder, Gait Disturbance
on Aug 04, 2010 Male patient from UNITED STATES , 68 years of age, was treated with Olanzapine (View Usage). Patient had the following side effects: cognitive disorder, expressive language disorder, gait disturbance. Olanzapine dosage: . Patient was hospitalized.

6914842-1 | Dyskinesia, Serotonin Syndrome
Patient was taking Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: dyskinesia, serotonin syndrome on Aug 04, 2010 from UNITED STATES Additional patient health information: Male patient , 75 years of age, . Olanzapine dosage: 5 Mg Every Day Po. Patient was hospitalized.

6913932-7 | Blood Creatine Phosphokinase Increased
Adverse event was reported on Aug 06, 2010 by a Male patient taking Olanzapine (View Usage) (Dosage: 10 Mg Every Day Po) was diagnosed with schizoaffective disorder and. Location: UNITED STATES , 79 years of age, weighting 130.1 lb, Patient experienced the following unwanted or unexpected effects: blood creatine phosphokinase increased.

6908064-8 | Aggression, Anger, Mood Swings, Suicidal Ideation, Weight Increased
on Jul 27, 2010 Male patient from UNITED STATES , weighting 112.0 lb, was diagnosed with bipolar i disorder, bipolar disorder (What is bipolar disorder?) and was treated with Olanzapine (View Usage). Patient had the following side effects: aggression, anger, mood swings, suicidal ideation, weight increased. Olanzapine dosage: 7.5 Mg, Daily (1/d). During the same period patient was treated with LITHIUM /00033701/ (300 Mg, 2/d) (View Lithium /00033701/ Review and Lithium /00033701/ Label ). Patient was hospitalized.

6905866-9 | Blood Creatine Phosphokinase Increased, C-reactive Protein Increased, Camptocormia, Rhabdomyolysis, Transaminases Increased
on Jul 22, 2010 Female patient from FRANCE , 73 years of age, was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: blood creatine phosphokinase increased, c-reactive protein increased, camptocormia, rhabdomyolysis, transaminases increased. Olanzapine dosage: 5 Mg, Daily (1/d). Patient was hospitalized.

6895028-6 | Hallucination, Auditory, Homicide, Hospitalisation
Patient was taking Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: hallucination, auditory, homicide, hospitalisation on Jul 19, 2010 from CANADA Additional patient health information: Male patient , 41 years of age, . Olanzapine dosage: 20 Mg, Unk. Patient was hospitalized.

6867261-0 | Completed Suicide, Off Label Use
Adverse event was reported on Jul 09, 2010 by a Female patient taking Olanzapine (View Usage) (Dosage: 10 Mg, Daily (1/d)) was diagnosed with major depression and. Location: EL SALVADOR , 23 years of age, Patient had the following side effects: completed suicide, off label use. During the same period patient was treated with PAROXETINE HCL (20 Mg, Daily (1/d)) (View Paroxetine Hcl Review and Paroxetine Hcl Label ), EFFEXOR (View Effexor Review and Effexor Label ).

6840632-4 | Azoospermia
on Jul 01, 2010 Male patient from UNITED KINGDOM , 22 years of age, was diagnosed with depression (What is depression?) and was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: azoospermia. Olanzapine dosage: 10 Mg, 2/d. During the same period patient was treated with DOSULEPIN (150 Mg, Daily (1/d)) (View Dosulepin Review and Dosulepin Label ).

6840625-7 | Respiratory Depression
on Jul 01, 2010 Male patient from MALAYSIA , 42 years of age, weighting 143.3 lb, was diagnosed with bipolar disorder (What is bipolar disorder?), mania, extrapyramidal disorder, aggression and was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: respiratory depression. Olanzapine dosage: 10 Mg, 2/d. During the same period patient was treated with LORAZEPAM (1 Mg, 3/d) (View Lorazepam Review and Lorazepam Label ), CHLORPROMAZINE (200 Mg, 3/d) (View Chlorpromazine Review and Chlorpromazine Label ), VALPROATE SODIUM (400 Mg, 2/d) (View Valproate Sodium Review and Valproate Sodium Label ), BENZHEXOL (2 Mg, 2/d) (View Benzhexol Review and Benzhexol Label ), ZIPRASIDONE HCL (20 Mg, Other (stat)) (View Ziprasidone Hcl Review and Ziprasidone Hcl Label ).

6836380-7 | Dyspnoea, Pulmonary Embolism
Patient was taking Olanzapine (View Usage). Patient had the following side effects: dyspnoea, pulmonary embolism (What is pulmonary embolism?) on Jun 30, 2010 from EL SALVADOR Additional patient health information: Male patient , 85 years of age, was diagnosed with psychotic disorder (What is psychotic disorder?) and. Olanzapine dosage: 5 Mg, Each Evening.

6836374-1 | Pulmonary Embolism
Adverse event was reported on Jun 30, 2010 by a Female patient taking Olanzapine (View Usage) (Dosage: ) was diagnosed with bipolar disorder (What is bipolar disorder?), insomnia and. Location: COSTA RICA , 70 years of age, After Olanzapine was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with LORAZEPAM (View Lorazepam Review and Lorazepam Label ), LITHIUM (View Lithium Review and Lithium Label ). Patient was hospitalized.

6833589-3 | Catatonia, Eating Disorder, Haemorrhage, Overdose, Tracheal Injury
on Jun 29, 2010 Female patient from NEW ZEALAND , 49 years of age, was diagnosed with schizophrenia and was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: catatonia, eating disorder (What is eating disorder?), haemorrhage, overdose, tracheal injury. Olanzapine dosage: 30 Mg, Unk. During the same period patient was treated with LORAZEPAM (10 Mg, Unk) (View Lorazepam Review and Lorazepam Label ). Patient was hospitalized.

6790806-6 | Deep Vein Thrombosis
on Jun 11, 2010 Male patient from UNITED KINGDOM , 43 years of age, was diagnosed with schizophrenia and was treated with Olanzapine (View Usage). Patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?). Olanzapine dosage: 10 Mg, Unk.

6784214-1 | Cardio-respiratory Arrest, Loss Of Consciousness, Spasmodic Dysphonia
Patient was taking Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: cardio-respiratory arrest, loss of consciousness, spasmodic dysphonia on Jun 07, 2010 from TURKEY Additional patient health information: Male patient , 36 years of age, . Olanzapine dosage: . During the same period patient was treated with HALOPERIDOL (View Haloperidol Review and Haloperidol Label ), CHLORPROMAZINE (View Chlorpromazine Review and Chlorpromazine Label ), RISPERIDONE (View Risperidone Review and Risperidone Label ). Patient was hospitalized.

6772784-9 | Cardio-respiratory Arrest, Decreased Appetite, Dehydration, Feeling Abnormal, Hospitalisation
Adverse event was reported on Jun 03, 2010 by a Female patient taking Olanzapine (View Usage) (Dosage: 5 Mg, Daily (1/d)) was diagnosed with agitated depression and. Location: GUATEMALA , 72 years of age, Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, decreased appetite, dehydration, feeling abnormal, hospitalisation. During the same period patient was treated with CYMBALTA (60 Mg, Daily (1/d)) (View Cymbalta Review and Cymbalta Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ). Patient was hospitalized.

6768157-5 | Mania
on May 17, 2010 Female patient from PANAMA , weighting 189.0 lb, was diagnosed with bipolar i disorder and was treated with Olanzapine (View Usage). Patient had the following side effects: mania. Olanzapine dosage: . Patient was hospitalized.

6767964-2 | Cerebrovascular Accident
on Jun 02, 2010 Female patient from UNITED KINGDOM , 66 years of age, was diagnosed with bipolar i disorder and was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: cerebrovascular accident. Olanzapine dosage: 5 Mg, Unk. During the same period patient was treated with VENLAFAXINE (75 Mg, Unk) (View Venlafaxine Review and Venlafaxine Label ), ADCAL D3 (View Adcal-d3 Review and Adcal-d3 Label ), ASASANTIN /00580301/ (View Asasantin /00580301/ Review and Asasantin /00580301/ Label ), ASCORBIC ACID (View Ascorbic Acid Review and Ascorbic Acid Label ), CLOPIDOGREL (View Clopidogrel Review and Clopidogrel Label ), MOVICOL /01749801/ (View Movicol /01749801/ Review and Movicol /01749801/ Label ), NIQUITIN (View Niquitin Review and Niquitin Label ), NICOTINE (View Nicotine Review and Nicotine Label ). Patient was hospitalized and became disabled.

6767955-1 | Mobility Decreased, Oedema Peripheral, Pain In Extremity
Patient was taking Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: mobility decreased, oedema peripheral, pain in extremity on Jun 02, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 55 years of age, was diagnosed with psychotic disorder (What is psychotic disorder?), anxiety (What is anxiety?), salivary hypersecretion, affective disorder and. Olanzapine dosage: 20 Mg, Daily (1/d). During the same period patient was treated with AMISULPRIDE (800 Mg, Daily (1/d)) (View Amisulpride Review and Amisulpride Label ), CITALOPRAM HYDROBROMIDE (20 Mg, Daily (1/d)) (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), DIAZEPAM (5 Mg, As Needed) (View Diazepam Review and Diazepam Label ), ELLESTE DUET (1 Mg, 4/w) (View Elleste-duet Review and Elleste-duet Label ), HALOPERIDOL (1 Mg, 4/d) (View Haloperidol Review and Haloperidol Label ), HYOSCINE HBR HYT (300 Ug, Other 5 Per Day) (View Hyoscine Hbr Hyt Review and Hyoscine Hbr Hyt Label ), VALPROATE SODIUM (500 Mg, 2/d) (View Valproate Sodium Review and Valproate Sodium Label ).

6764007-1 | Dyskinesia, Panic Attack, Tachyphrenia, Tardive Dyskinesia
Adverse event was reported on May 28, 2010 by a Male patient taking Olanzapine (View Usage) (Dosage: ) was diagnosed with schizophrenia and. Location: UNITED KINGDOM , 27 years of age, weighting 220.5 lb, Patient had the following side effects: dyskinesia, panic attack, tachyphrenia, tardive dyskinesia. During the same period patient was treated with RISPERDAL CONSTA (50 Mg, Unk) (View Risperdal Consta Review and Risperdal Consta Label ).

6762452-1 | Arteriosclerosis Coronary Artery, Off Label Use
on May 28, 2010 Male patient from UNITED KINGDOM , 27 years of age, weighting 122.0 lb, was diagnosed with anxiety (What is anxiety?), depression (What is depression?) and was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: arteriosclerosis coronary artery, off label use. Olanzapine dosage: 5 Mg, 4/d. During the same period patient was treated with CITALOPRAM (40 Mg, Unk) (View Citalopram Review and Citalopram Label ), DF118 (30 Mg, 4/d) (View Df118 Review and Df118 Label ), GABAPENTIN (300 Mg, Unk) (View Gabapentin Review and Gabapentin Label ).

6759360-9 | Blood Glucose Decreased, Blood Pressure Decreased, Loss Of Consciousness
on May 26, 2010 Male patient from INDONESIA , 22 years of age, weighting 110.2 lb, was diagnosed with paranoia and was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: blood glucose decreased, blood pressure decreased, loss of consciousness. Olanzapine dosage: 10 Mg, Daily (1/d). During the same period patient was treated with RISPERIDONE (4 Mg, Unk) (View Risperidone Review and Risperidone Label ), TRIHEXYPHENIDYL HCL (2 D/f, Unk) (View Trihexyphenidyl Hcl Review and Trihexyphenidyl Hcl Label ).

6753855-X | Blood Creatinine Increased, Infection, Labile Blood Pressure, Neuroleptic Malignant Syndrome, Pyrexia, Stress
Patient was taking Olanzapine (View Usage). Patient had the following side effects: blood creatinine increased, infection (What is infection?), labile blood pressure, neuroleptic malignant syndrome, pyrexia, stress (What is stress?) on May 20, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 45 years of age, was diagnosed with psychotic disorder (What is psychotic disorder?) and. Olanzapine dosage: 10 Mg, Unk. During the same period patient was treated with HALOPERIDOL (5 Mg, Unk) (View Haloperidol Review and Haloperidol Label ), CITALOPRAM (View Citalopram Review and Citalopram Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), QUETIAPINE (View Quetiapine Review and Quetiapine Label ). Patient was hospitalized.

6750585-5 | Chest Pain, Dyspnoea
Adverse event was reported on May 28, 2010 by a Female patient taking Olanzapine (View Usage) (Dosage: ) . Location: UNITED STATES , 15 years of age, After Olanzapine was administered, patient had the following side effects: chest pain (What is chest pain?), dyspnoea. Patient was hospitalized.

6750424-2 | Cerebrovascular Accident, Muscular Weakness
on May 19, 2010 Male patient from UNITED KINGDOM , 50 years of age, was diagnosed with psychotic disorder (What is psychotic disorder?), depressed mood and was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrovascular accident, muscular weakness. Olanzapine dosage: . During the same period patient was treated with DULOXETINE HYDROCHLORIDE (View Duloxetine Hydrochloride Review and Duloxetine Hydrochloride Label ).

6740383-0 | Hepatic Steatosis, Liver Function Test Abnormal, Off Label Use, Serum Ferritin Increased
on May 14, 2010 Male patient from UNITED KINGDOM , 26 years of age, was diagnosed with major depression and was treated with Olanzapine (View Usage). Patient had the following side effects: hepatic steatosis, liver function test abnormal, off label use, serum ferritin increased. Olanzapine dosage: 20 Mg, Daily (1/d).

6736786-0 | Abnormal Behaviour, Bladder Obstruction, Confusional State, Constipation, Delirium, Disability, Electrocardiogram Qt Prolonged, Fall, Fatigue
Patient was taking Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: abnormal behaviour, bladder obstruction, confusional state, constipation (What is constipation?), delirium, disability, electrocardiogram qt prolonged, fall (What is fall?), fatigue on May 09, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 90 years of age, was diagnosed with dementia (What is dementia?) and. Olanzapine dosage: 10 Mg, Unk. During the same period patient was treated with DONEPEZIL HCL (View Donepezil Hcl Review and Donepezil Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6734397-4 | Anaemia Megaloblastic, Gastrooesophageal Reflux Disease, Pancytopenia
Adverse event was reported on May 10, 2010 by a Male patient taking Olanzapine (View Usage) (Dosage: 20 Mg, Daily (1/d)) was diagnosed with schizophrenia and. Location: FRANCE , 56 years of age, Patient experienced the following unwanted or unexpected effects: anaemia megaloblastic, gastrooesophageal reflux disease, pancytopenia. During the same period patient was treated with HALOPERIDOL DECANOATE (3 Mg, Every 3 Weeks) (View Haloperidol Decanoate Review and Haloperidol Decanoate Label ), LOXAPINE (100 Mg, Daily (1/d)) (View Loxapine Review and Loxapine Label ), AMISULPRIDE (800 Mg, Daily (1/d)) (View Amisulpride Review and Amisulpride Label ), TROPATEPINE (10 Mg, Daily (1/d)) (View Tropatepine Review and Tropatepine Label ), DIAZEPAM (10 Mg, Daily (1/d)) (View Diazepam Review and Diazepam Label ), CLORAZEPATE DIPOTASSIUM (50 Mg, Daily (1/d)) (View Clorazepate Dipotassium Review and Clorazepate Dipotassium Label ). Patient was hospitalized.

6727107-8 | Schizophrenia
on May 10, 2010 Male patient from RUSSIAN FEDERATION , weighting 161.6 lb, was diagnosed with schizophrenia and was treated with Olanzapine (View Usage). Patient had the following side effects: schizophrenia. Olanzapine dosage: 20 Mg, Daily (1/d). Patient was hospitalized.

6722516-5 | Leukopenia, Neutropenia, Neutrophil Count Decreased, White Blood Cell Count Decreased
on Apr 30, 2010 Female patient from UNITED KINGDOM , 29 years of age, was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: leukopenia, neutropenia, neutrophil count decreased, white blood cell count decreased. Olanzapine dosage: 10 Mg, Each Evening. During the same period patient was treated with ZAPONEX (View Zaponex Review and Zaponex Label ), SODIUM VALPROATE (20 Mg, Daily (1/d)) (View Sodium Valproate Review and Sodium Valproate Label ), LEVOTHYROXINE SODIUM (100 Ug, Unk) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ).

6716542-X | Hyperchloraemia, Hyperglycaemia, Hyperosmolar State
Patient was taking Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: hyperchloraemia, hyperglycaemia, hyperosmolar state on Apr 27, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 44 years of age, was diagnosed with psychotic disorder (What is psychotic disorder?), vitamin supplementation and. Olanzapine dosage: 10 Mg, Daily (1/d). During the same period patient was treated with VITAMIN B 12 (View Vitamin B-12 Review and Vitamin B-12 Label ), METFORMIN (View Metformin Review and Metformin Label ).

6715071-7 | Catatonia, Dystonia, Mental Status Changes, Urinary Tract Infection
Adverse event was reported on May 06, 2010 by a Male patient taking Olanzapine (View Usage) (Dosage: 30mg Po Daily (out Pt Dose)) was diagnosed with bipolar disorder (What is bipolar disorder?), schizophrenia and. Location: UNITED STATES , 63 years of age, weighting 120.0 lb, Patient had the following side effects: catatonia, dystonia (What is dystonia?), mental status changes, urinary tract infection (What is urinary tract infection?). During the same period patient was treated with AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), TAMSULOSIN HCL (View Tamsulosin Hcl Review and Tamsulosin Hcl Label ). Patient was hospitalized.

6714325-8 | Endocarditis, Liver Disorder, Pyrexia, Splenomegaly
on Apr 26, 2010 Female patient from HUNGARY , 50 years of age, was diagnosed with schizophrenia and was treated with Olanzapine (View Usage). After Olanzapine was administered, patient had the following side effects: endocarditis (What is endocarditis?), liver disorder, pyrexia, splenomegaly. Olanzapine dosage: 10 Mg, Daily (1/d).

6712271-7 | Acute Psychosis, Agitation, Cognitive Disorder, Emotional Disorder, Extrapyramidal Disorder, Head Titubation, Hospitalisation, Mental Impairment
on Apr 23, 2010 Female patient from POLAND , 20 years of age, weighting 119.0 lb, was diagnosed with psychotic disorder (What is psychotic disorder?), schizophrenia, paranoid type, tremor and was treated with Olanzapine (View Usage). Patient experienced the following unwanted or unexpected effects: acute psychosis, agitation, cognitive disorder, emotional disorder, extrapyramidal disorder, head titubation, hospitalisation, mental impairment. Olanzapine dosage: . During the same period patient was treated with ZYPREXA (10 Mg, Unk) (View Zyprexa Review and Zyprexa Label ), LITHIUM CARBONATE (View Lithium Carbonate Review and Lithium Carbonate Label ), AMISULPRIDE (View Amisulpride Review and Amisulpride Label ), ABILIFY (15 Mg, Unk) (View Abilify Review and Abilify Label ), PROPRANOLOL (10 Mg, Unk) (View Propranolol Review and Propranolol Label ). Patient was hospitalized.

6705251-9 | Blood Glucose Decreased, Blood Pressure Decreased, Loss Of Consciousness
Patient was taking Olanzapine (View Usage). Patient had the following side effects: blood glucose decreased, blood pressure decreased, loss of consciousness on Apr 19, 2010 from INDONESIA Additional patient health information: Male patient , 22 years of age, weighting 110.2 lb, was diagnosed with paranoia and. Olanzapine dosage: 10 Mg, Daily (1/d). During the same period patient was treated with RISPERIDONE (4 Mg, Unk) (View Risperidone Review and Risperidone Label ), TRIHEXYPHENIDYL HCL (2 D/f, Unk) (View Trihexyphenidyl Hcl Review and Trihexyphenidyl Hcl Label ).